Prediction of development of liver-related events by transient elastography in Hepatitis B patients with complete virological response on antiviral therapy

American Journal of Gastroenterology

Volumn 109, Issue 8, 2014, Pages 1241-1249

  Lee, Hye Won ^a   Yoo, Eun Jin ^a   Kim, Beom Kyung ^a,b   Kim, Seung Up ^a,b   Park, Jun Yong ^a,b   Kim, Do Young ^a,b   Ahn, Sang Hoon ^a,b,c   Han, Kwang Hyub ^a,b,c  

^a Yonsei University College of Medicine   (South Korea)

^b Liver Cirrhosis Clinical Research Centre   (South Korea)

^c Yonsei University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANTIVIRAL AGENTS; ELASTICITY IMAGING TECHNIQUES; FEMALE; GUANINE; HEPATITIS B, CHRONIC; HUMANS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REPUBLIC OF KOREA; TUMOR MARKERS, BIOLOGICAL;

EID: 84905585191     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2014.157     Document Type: Article

References (44)

1. Ringelhan M, Heikenwalder M, Protzer U. Direct effects of hepatitis B virus-encoded proteins and chronic infection in liver cancer development. Dig Dis 2013; 31 : 138-51.
2. Iloeje UH, Yang HI, Su J et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130 : 678-86.
3. Chan HL, Tse CH, Mo F et al. High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol 2008; 26 : 177-82.
4. Liaw YF, Sung JJ, Chow WC et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351 : 1521-31.
5. Wong VW, Wong GL, Chim AM et al. Surrogate end points and long-term outcome in patients with chronic hepatitis B. Clin Gastroenterol Hepatol 2009; 7 : 1113-20.
6. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57 : 167-85.
7. Liaw YF, Leung N, Kao JH et al. Asian-Pacifi c consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2 : 263-83.
8. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50 : 661-2.
9. Chang TT, Lai CL, Kew Yoon S et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010; 51 : 422-30.
10. Wong GL, Wong VW, Chan HY et al. Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years. Aliment Pharmacol Ther 2012; 35 : 1326-35.
11. Wong GL, Chan HL, Mak CH et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 2013; 58 : 1537-47.
12. Ganne-Carrie N, Ziol M, de Ledinghen V et al. Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. Hepatology 2006; 44 : 1511-7.
13. Ziol M, Handra-Luca A, Kettaneh A et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005; 41 : 48-54.
14. Sirli R, Sporea I, Tudora A et al. Transient elastographic evaluation of subjects without known hepatic pathology: does age change the liver stiffness? J Gastrointestin Liver Dis 2009; 18 : 57-60.
15. KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clin Mol Hepatol 2012; 18 : 109-62.
16. Jung KS, Kim SU, Ahn SH et al. Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology 2011; 53 : 885-94.
17. Kim BK, Fung J, Yuen MF et al. Clinical application of liver stiffness measurement using transient elastography in chronic liver disease from longitudinal perspectives. World J Gastroenterol 2013; 19 : 1890-900.
18. Kim SU, Lee JH, Kim do Y et al. Prediction of liver-related events using fi broscan in chronic hepatitis B patients showing advanced liver fibrosis. PLoS One 2012; 7 : e36676.
19. Chon YE, Jung ES, Park JY et al. The accuracy of noninvasive methods in predicting the development of hepatocellular carcinoma and hepatic decompensation in patients with chronic hepatitis B. J Clin Gastroenterol 2012; 46 : 518-25.
20. Heagerty PJ, Zheng Y. Survival model predictive accuracy and ROC curves. Biometrics 2005; 61 : 92-105.
21. Yang HI, Yuen MF, Chan HL et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol 2011; 12 : 568-74.
22. Hsu YS, Chien RN, Yeh CT et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002; 35 : 1522-7.
23. Fattovich G, Brollo L, Giustina G et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991; 32 : 294-8.
24. Huo T, Wu JC, Hwang SJ et al. Factors predictive of liver cirrhosis in patients with chronic hepatitis B: a multivariate analysis in a longitudinal study. Eur J Gastroenterol Hepatol 2000; 12 : 687-93.
25. Lin SM, Sheen IS, Chien RN et al. Long-term benefi cial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999; 29 : 971-5.
26. Liaw YF, Tai DI, Chu CM et al. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988; 8 : 493-6.
27. Chen CJ, Yang HI, Su J et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295 : 65-73.
28. Chen CJ, Iloeje UH, Yang HI. Long-term outcomes in hepatitis B: the REVEAL-HBV study. Clin Liver Dis 2007; 11 : 797-816, viii.
29. Chang TT, Liaw YF, Wu SS et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52 : 886-93.
30. Parkes J, Roderick P, Harris S et al. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut 2010; 59 : 1245-51.
31. Pungpapong S, Kim WR, Poterucha JJ. Natural history of hepatitis B virus infection: an update for clinicians. Mayo Clin Proc 2007; 82 : 967-75.
32. Kim SU, Choi GH, Han WK et al. What are ' true normal' liver stiffness values using FibroScan?: a prospective study in healthy living liver and kidney donors in South Korea. Liver Int 2010; 30 : 268-74.
33. Park BK, Park YN, Ahn SH et al. Long-term outcome of chronic hepatitis B based on histological grade and stage. J Gastroenterol Hepatol 2007; 22 : 383-8.
34. Hann HW, Kim CY, London WT et al. Hepatitis B virus and primary hepatocellular carcinoma: family studies in Korea. Int J Cancer 1982; 30 : 47-51.
35. Park YH, Kim BK, Kim JK et al. Long-term outcomes of chronic hepatitis B virus infection in the era of antiviral therapy in Korea. J Gastroenterol Hepatol 2014; 29 : 1005-11.
36. Wong GL, Chan HL, Yu Z et al. Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B-a prospective cohort study with paired transient elastography examinations. Aliment Pharmacol Ther 2014; 39 : 883-93.
37. Corrao G, Torchio P, Zambon A et al. Exploring the combined action of lifetime alcohol intake and chronic hepatotropic virus infections on the risk of symptomatic liver cirrhosis. Collaborative Groups for the Study of Liver Diseases in Italy. Eur J Epidemiol 1998; 14 : 447-56.
38. Wong GL, Wong VW, Choi PC et al. Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. Gut 2009; 58 : 111-7.
39. Asselah T, Rubbia-Brandt L, Marcellin P et al. Steatosis in chronic hepatitis C: why does it really matter? Gut 2006; 55 : 123-30.
40. Kim MN, Kim SU, Park JY et al. Risk assessment of liver-related events using transient elastography in patients with chronic hepatitis B receiving entecavir. J Clin Gastroenterol 2014; 48 : 272-8.
41. Kim BK, Oh HJ, Park JY et al. Early on-treatment change in liver stiffness predicts development of liver-related events in chronic hepatitis B patients receiving antiviral therapy. Liver Int 2013; 33 : 180-9.
42. Coco B, Oliveri F, Maina AM et al. Transient elastography: a new surrogate marker of liver fibrosis infl uenced by major changes of transaminases. J Viral Hepat 2007; 14 : 360-9.
43. Sagir A, Erhardt A, Schmitt M et al. Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage. Hepatology 2008; 47 : 592-5.
44. Kim SU, Kim do Y, Ahn SH et al. The impact of steatosis on liver stiffness measurement in patients with chronic hepatitis B. Hepatogastroenterology 2010; 57 : 832-8.